bluebird bio anticipates the total gross proceeds from the offering
(before deducting underwriters’ discounts and commissions and estimated
offering expenses) will be approximately
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio’s gene therapy clinical programs include its Lenti-D™ product
candidate, currently in a Phase 2/3 study, called the Starbeam Study,
for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin®
BB305 product candidate, currently in four clinical studies for the
treatment of transfusion-dependent beta-thalassemia and severe sickle
cell disease. bluebird bio’s oncology pipeline is built upon the
company’s leadership in lentiviral gene delivery and T cell engineering,
with a focus on developing novel T cell-based immunotherapies, including
chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies.
bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T
program partnered with
bluebird bio has operations in
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the anticipated final terms, timing and completion
of the offering, and bluebird bio’s existing product candidates and
research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related to
the public offering, that the preliminary positive results from our
prior and ongoing clinical trials will not continue or be repeated in
our ongoing, planned or expanded clinical trials, the risk that the
changes we have made in the LentiGlobin manufacturing process or the
HGB-206 clinical trial protocol will not result in improved patient
outcomes, the risk that the current or planned clinical trials of
LentiGlobin and Lenti-D will be insufficient to support regulatory
submissions or marketing approval in the
Source: bluebird bio, Inc.
bluebird bio, Inc.
Manisha Pai, 617-245-2107
bluebird bio, Inc.
Elizabeth Pingpank, 617-914-8736
Pure Communications, Inc.
Dan Budwick, 973-271-6085